A 2-Week, Randomized, Double Blind, Placebo Controlled, Parallel-Group, Phase 2, Multicenter Study Of Pf-04136309 In Subjects With Osteoarthritic Pain Of The Knee
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2012
At a glance
- Drugs PF 4136309 (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 25 Dec 2008 Status changed from recruiting to completed.
- 18 Dec 2008 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 15 Dec 2008 Planned number of patients changed from 152 to 160 as reported by ClinicalTrials.gov.